Circadian rhythm disruption by PARP inhibitors correlates with treatment toxicity in patients with ovarian cancer and is a predictor of side effects.

Journal: EBioMedicine
Published Date:

Abstract

BACKGROUND: Ovarian cancer is among the most lethal malignancies in women. The advent of PARP inhibitors (PARPi) has improved outcomes. However, treatment-related toxicity remains a critical challenge, impacting patient quality of life and treatment adherence.

Authors

  • Deeksha Malhan
    Institute for Systems Medicine and Faculty of Human Medicine, MSH Medical School Hamburg, Hamburg, Germany.
  • Janina Hesse
    Institute for Systems Medicine and Faculty of Human Medicine, MSH Medical School Hamburg, Hamburg, Germany; Leibniz-Institute for Resilience Research (LIR), Mainz, Germany; Johannes Gutenberg University Medical Center Mainz, Mainz, Germany; Institute for Quantitative and Computational Biosciences (IQCB), Johannes-Gutenberg University, Mainz, Germany.
  • Nina Nelson
    Institute for Systems Medicine and Faculty of Human Medicine, MSH Medical School Hamburg, Hamburg, Germany.
  • Kay Stankov
    Stat4med (Ainovate GmbH), Frankfurt, Germany.
  • Jessica Nguyen
    Center for Robotic Simulation and Education, USC Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Ouda Aboumanify
    Institute for Theoretical Biology (ITB), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Josefin Garmshausen
    Institute for Systems Medicine and Faculty of Human Medicine, MSH Medical School Hamburg, Hamburg, Germany; Institute for Theoretical Biology (ITB), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Gunther Rogmans
    North-Eastern German Society of Gynecological Oncology (NOGGO e.V.), Berlin, Germany; ZAGO- Zentrum für ambulante gynäkologische Onkologie, Krefeld, Germany.
  • Bastian Czogalla
    North-Eastern German Society of Gynecological Oncology (NOGGO e.V.), Berlin, Germany; Department of Obstetrics and Gynecology, LMU University Hospital, LMU Munich, Munich, Germany.
  • Jens Gerber
    North-Eastern German Society of Gynecological Oncology (NOGGO e.V.), Berlin, Germany; Städtisches Klinikum Dessau, Frauenheilkunde und Geburtshilfe, Dessau, Germany.
  • Martin Koch
    OSTHUS, Aachen, Germany.
  • Tomáš Kupec
    North-Eastern German Society of Gynecological Oncology (NOGGO e.V.), Berlin, Germany; Department of Obstetrics and Gynecology, University Hospital Aachen, Aachen, Germany.
  • Oliver Tomé
    North-Eastern German Society of Gynecological Oncology (NOGGO e.V.), Berlin, Germany; ViDia Christliche Kliniken Karlsruhe, Department of Gynecology and Obstetrics, Karlsruhe, Germany.
  • Ralf Witteler
    North-Eastern German Society of Gynecological Oncology (NOGGO e.V.), Berlin, Germany; Universitätsklinikum Münster, Klinik für Frauenheilkunde und Geburtshilfe, Münster, Germany.
  • Mustafa Deryal
    North-Eastern German Society of Gynecological Oncology (NOGGO e.V.), Berlin, Germany; Center for Gynecology, Caritas Klinikum St. Theresia-Saarbruecken, Saarbruecken, Germany.
  • Michael Eichbaum
    North-Eastern German Society of Gynecological Oncology (NOGGO e.V.), Berlin, Germany; Helios Dr. Horst Schmidt Kliniken Wiesbaden, Department of Gynecology and Obstetrics, Wiesbaden, Germany.
  • Jalid Sehouli
    Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
  • Elena Ioana Braicu
    North-Eastern German Society of Gynecological Oncology (NOGGO e.V.), Berlin, Germany; Department of Gynecology with Center for Oncological Surgery, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany; Tumorbank Ovarian Cancer Network, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. Electronic address: elena.braicu@charite.de.
  • Angela Relógio
    Institute for Systems Medicine and Faculty of Human Medicine, MSH Medical School Hamburg, Hamburg, Germany; Institute for Theoretical Biology (ITB), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; TimeTeller GmbH, Hamburg, Germany. Electronic address: angela.relogio@medicalschool-hamburg.de.

Keywords

No keywords available for this article.